Quanterix Corporation Awarded $185,000 Grant From The National Cancer Institute
Leader in single molecule protein detection will utilize funds to develop single molecule arrays for the detection of low abundance cancer proteins
Cambridge, MA – Quanterix Corporation, the leader in single molecule protein detection, announced today that it has been awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Cancer Institute of the National Institutes of Health (NIH). This grant supports development of the company’s SingleMolecule Array (SiMoA™) technology to develop ultrasensitive assays for the detection of proteins implicated in cancer.
Dr. Nicholas Naclerio, Chairman and CEO of Quanterix said “Quanterix’s platform will allow diseases to be detected at the earliest stages to increase the likelihood that treatments can alleviate or stabilize the disease process and help ensure positive patient outcomes. The application of this technology will provide medical researchers with an unprecedented tool for detecting low abundance biological molecules, and facilitate the development of a new generation of diagnostic products useful for early detection of diseases, including cancer.”
Dr. David Duffy, Senior Director of Platform Technology and Principal Investigator for the grant added “This SBIR award recognizes the potential of SiMoA™ to measure low abundance proteins in serum. Funding will be used to develop and validate assays and instrumentation that enable extremely high sensitivity measurements of cancer markers.”
The Small Business Innovative Research program is designed to stimulate technological innovation among private business, and provide cost-effective solutions to challenging problems. The project proposal addresses several aspects of the NIH mission to develop innovative research strategies towards improving diagnosis, prevention and cure of human diseases.
Quanterix is developing a revolutionary Single Molecule Array (SiMoA™) technology that allows the behavior ofthousands of individual molecules to be observed simultaneously, rather than an ensemble average of many molecules as with existing technologies. The first application that Quanterix is pursuing with the SiMoA™ technology is the detection and quantification of proteins present in blood and other body fluids at very low, previously undetectable, concentrations. Diagnostic assays targeting proteins that have been implicated in a variety of human diseases, including cancer, chronic inflammatory disease and cardiovascular disease are under development. Quanterix is a privately held company located in Cambridge, Massachusetts. For additional information, please visit www.quanterix.com.
Share this page